Skip to main content

Advertisement

SpringerLink
Log in

Endocan, a new invasion and angiogenesis marker of pituitary adenomas

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Angiogenesis plays a crucial role in tumor growth. Recently, endocan has emerged as a new marker of vascular endothelial cells from cancers in other organs. In this study, we elucidated the relationship between endocan expression and tumor invasion of pituitary adenoma. Tumor tissues were obtained from 70 patients with pituitary adenoma and were examined using fluorescence immunohistochemistry. Tissue samples included 4 adrenocorticotrophic hormone producing adenomas, 10 growth hormone-producing adenomas, 49 clinically nonfunctioning adenomas, 6 prolactin producing adenomas, and 1 thyroid-stimulating hormone producing adenoma. Endocan was exclusively expressed in CD34-positive vascular endothelial cells, with over 90 % colocalization. The CD34 expression was significantly elevated with endocan expression (linear regression slope, 1.200; r2 = 0.268, F = 23.08, p < 0.0001). As a percentage of CD34 expression, endocan expression was elevated in a Knosp grading dependent manner (Spearman’s r-value, 0.651; p < 0.0001), and was also significantly elevated in macroadenomas compared with microadenomas (p = 0.0133). However, no differences in endocan expression were observed between hormonal subtypes (p = 0.066; Kruskal–Wallis test), age (Spearman’s rank correlation test, p = 0.4909), or sex (Mann–Whitney test, p = 0.1701). These data show that endocan is closely related to tumor angiogenesis, and may predict tumor invasion into neighboring cavernous sinuses in pituitary adenomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Di Ieva A, Grizzi F, Ceva-Grimaldi G, Aimar E, Serra S, Pisano P, Lorenzetti M, Tancioni F, Gaetani P, Crotti F, Tschabitscher M, Matula C, Rodriguez YBR (2010) The microvascular network of the pituitary gland: a model for the application of fractal geometry to the analysis of angioarchitecture and angiogenesis of brain tumors. J Neurosurg Sci 54:49–54

    PubMed  Google Scholar 

  2. Di Ieva A, Weckman A, Di Michele J, Rotondo F, Grizzi F, Kovacs K, Cusimano MD (2013) Microvascular morphometrics of the hypophysis and pituitary tumors: from bench to operating theatre. Microvasc Res 89:7–14. doi:10.1016/j.mvr.2013.04.009

    Article  PubMed  Google Scholar 

  3. Jasek E, Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F (2009) Microvessel density and area in pituitary microadenomas. Endocr Pathol 20:221–226. doi:10.1007/s12022-009-9091-1

    Article  CAS  PubMed  Google Scholar 

  4. Lee JS, Park YS, Kwon JT, Nam TK, Lee TJ, Kim JK (2011) Radiological apoplexy and its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in pituitary adenomas. J Korean Neurosurg Soc 50:281–287. doi:10.3340/jkns.2011.50.4.281

    Article  PubMed Central  PubMed  Google Scholar 

  5. Zhang Y, He N, Zhou J, Chen Y (2011) The relationship between MRI invasive features and expression of EMMPRIN, galectin-3, and microvessel density in pituitary adenoma. Clin Imaging 35:165–173. doi:10.1016/j.clinimag.2010.06.002

    Article  PubMed  Google Scholar 

  6. Yamada S, Takada K (2003) Angiogenesis in pituitary adenomas. Microsc Res Tech 60:236–243. doi:10.1002/jemt.10262

    Article  CAS  PubMed  Google Scholar 

  7. Nomura R, Yoshida D, Teramoto A (2009) Stromal cell-derived factor-1 expression in pituitary adenoma tissues and upregulation in hypoxia. J Neurooncol 94:173–181. doi:10.1007/s11060-009-9835-2

    Article  CAS  PubMed  Google Scholar 

  8. Abid MR, Yi X, Yano K, Shih SC, Aird WC (2006) Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 72:136–145. doi:10.1016/j.mvr.2006.05.010

    Article  CAS  PubMed  Google Scholar 

  9. Grigoriu BD, Depontieu F, Scherpereel A, Gourcerol D, Devos P, Ouatas T, Lafitte JJ, Copin MC, Tonnel AB, Lassalle P (2006) Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res Off J Am Assoc Cancer Res 12:4575–4582. doi:10.1158/1078-0432.ccr-06-0185

    Article  CAS  Google Scholar 

  10. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, Lortat-Jacob H, Bechard D, Lassalle P, Delehedde M (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37. doi:10.1016/j.bbcan.2005.08.004

    CAS  PubMed  Google Scholar 

  11. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, Jourdain M, Pugin J, Tonnel AB, Lassalle P (2006) Endocan, a new endothelial marker in human sepsis. Crit Care Med 34:532–537

    Article  CAS  PubMed  Google Scholar 

  12. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22:757–764. doi:10.1111/j.1750-3639.2012.00578.x

    Article  CAS  PubMed  Google Scholar 

  13. Filep JG (2006) Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis? Crit Care Med 34:574–575

    Article  PubMed  Google Scholar 

  14. Maurage CA, Adam E, Mineo JF, Sarrazin S, Debunne M, Siminski RM, Baroncini M, Lassalle P, Blond S, Delehedde M (2009) Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 68:633–641. doi:10.1097/NEN.0b013e3181a52a7f

    Article  CAS  PubMed  Google Scholar 

  15. Rennel E, Mellberg S, Dimberg A, Petersson L, Botling J, Ameur A, Westholm JO, Komorowski J, Lassalle P, Cross MJ, Gerwins P (2007) Endocan is a VEGF-A and PI3 K regulated gene with increased expression in human renal cancer. Exp Cell Res 313:1285–1294. doi:10.1016/j.yexcr.2007.01.021

    Article  CAS  PubMed  Google Scholar 

  16. Zuo L, Zhang SM, Hu RL, Zhu HQ, Zhou Q, Gui SY, Wu Q, Wang Y (2008) Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol WJG 14:4562–4568

    Article  CAS  Google Scholar 

  17. Huang GW, Tao YM, Ding X (2009) Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 54:389–394. doi:10.1007/s10620-008-0346-3

    Article  CAS  PubMed  Google Scholar 

  18. Hatfield KJ, Lassalle P, Leiva RA, Lindas R, Wendelboe O, Bruserud O (2011) Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology (Amsterdam, Netherlands) 16:351–356. doi:10.1179/102453311x13127324303434

    CAS  Google Scholar 

  19. Zhang S, Zuo L, Gui S, Zhou Q, Wei W, Wang Y (2012) Induction of cell differentiation and promotion of endocan gene expression in stomach cancer by melatonin. Mol Biol Rep 39:2843–2849. doi:10.1007/s11033-011-1043-4

    Article  CAS  PubMed  Google Scholar 

  20. El Behery MM, Seksaka MA, Ibrahiem MA, Saleh HS, El Alfy Y (2013) Clinicopathological correlation of endocan expression and survival in epithelial ovarian cancer. Arch Gynecol Obstet. doi:10.1007/s00404-013-2863-3

    Google Scholar 

  21. Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, Localio AR, Albelda SM, Meyer NJ, Christie JD (2012) Lower serum endocan levels are associated with the development of acute lung injury after major trauma. J Crit Care 27(522):e511–e527. doi:10.1016/j.jcrc.2011.07.077

    Google Scholar 

  22. Zhang SM, Zuo L, Zhou Q, Gui SY, Shi R, Wu Q, Wei W, Wang Y (2012) Expression and distribution of endocan in human tissues. Biotechnic Histochem Off Publ Biol Stain Comm 87:172–178. doi:10.3109/10520295.2011.577754

    Article  CAS  Google Scholar 

  23. Balta I, Balta S, Demirkol S, Mikhailidis DP, Celik T, Akhan M, Kurt O, Kurt YG, Aydin I, Kilic S (2013) Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease. Br J Dermatol. doi:10.1111/bjd.12525

    PubMed  Google Scholar 

  24. De Freitas Caires N, Legendre B, Parmentier E, Scherpereel A, Tsicopoulos A, Mathieu D, Lassalle P (2013) Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 78–79:45–51. doi:10.1016/j.jpba.2013.01.035

    Google Scholar 

  25. Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N’Kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lassalle P, Charnaux N, Delehedde M, Sutton A, Nahon P (2013) Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomark Prev. doi:10.1158/1055-9965.epi-13-0179

    Google Scholar 

  26. Roudnicky F, Poyet C, Wild P, Krampitz S, Negrini F, Huggenberger R, Rogler A, Stohr R, Hartmann A, Provenzano M, Otto VI, Detmar M (2013) Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 73:1097–1106. doi:10.1158/0008-5472.can-12-1855

    Article  CAS  PubMed  Google Scholar 

  27. Pizarro CB, Oliveira MC, Pereira-Lima JF, Leaes CG, Kramer CK, Schuch T, Barbosa-Coutinho LM, Ferreira NP (2009) Evaluation of angiogenesis in 77 pituitary adenomas using endoglin as a marker. Neuropathology Off J Jpn Soc Neuropathol 29:40–44. doi:10.1111/j.1440-1789.2008.00937.x

    Article  Google Scholar 

  28. Yoshida D, Nomura R, Teramoto A (2009) Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1alpha, in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol 21:481–488. doi:10.1111/j.1365-2826.2009.01867.x

    Article  CAS  PubMed  Google Scholar 

  29. Yoshida D, Koketshu K, Nomura R, Teramoto A (2010) The CXCR4 antagonist AMD3100 suppresses hypoxia-mediated growth hormone production in GH3 rat pituitary adenoma cells. J Neurooncol 100:51–64. doi:10.1007/s11060-010-0152-6

    Article  CAS  PubMed  Google Scholar 

  30. Viacava P, Gasperi M, Acerbi G, Manetti L, Cecconi E, Bonadio AG, Naccarato AG, Acerbi F, Parenti G, Lupi I, Genovesi M, Martino E (2003) Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas. J Endocrinol Invest 26:23–28

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan (Nos. 20591726 and 18390405).

Conflict of interest

There are no conflicts of interest for all authors. Fumihiro Matano who is a member of the JNS have registered on-line Self-reported COI Disclosure Statement Forms through the web-site for JNS members.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Nippon Medical School, 1-1-5, Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan

    Fumihiro Matano, Daizo Yoshida, Yudo Ishii, Shigeyuki Tahara, Akira Teramoto & Akio Morita

Authors
  1. Fumihiro Matano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daizo Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yudo Ishii
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shigeyuki Tahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akira Teramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akio Morita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fumihiro Matano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matano, F., Yoshida, D., Ishii, Y. et al. Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J Neurooncol 117, 485–491 (2014). https://doi.org/10.1007/s11060-014-1377-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1377-6

Keywords

Search

Navigation